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Background. Two different enzyme preparations, agalsidase alfa (Replagal
TM, Shire) and beta (Fabrazyme
TM, Genzyme), are
registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase
preparations administered at identical protein dose in a randomized controlled open label trial. Methodology/Principal
Findings. Thirty-four Fabry disease patients were treated with either agalsidase alfa or agalsidase beta at equal dose of
0.2 mg/kg biweekly. Primary endpoint was reduction in left ventricular mass after 12 and 24 months of treatment. Other
endpoints included occurrence of treatment failure (defined as progression of cardiac, renal or cerebral disease), glomerular
filtration rate, pain, anti-agalsidase antibodies, and globotriaosylceramide levels in plasma and urine. After 12 and 24 months
of treatment no reduction in left ventricular mass was seen, which was not different between the two treatment groups. Also,
no differences in glomerular filtration rate, pain and decline in globotriaosylceramide levels were found. Antibodies developed
only in males (4/8 in the agalsidase alfa group and 6/8 in the agalsidase beta group). Treatment failure within 24 months of
therapy was seen in 8/34 patients: 6 male patients (3 in each treatment group) and 2 female patients (both agalsidase alfa). The
occurrence of treatment failures did not differ between the two treatment groups; x
2=0.38 p=0.54. Conclusion. Our study
revealed no difference in reduction of left ventricular mass or other disease parameters after 12 and 24 months of treatment
with either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly. Treatment failure occurred frequently in both groups and
seems related to age and severe pre-treatment disease. Trial Registration. International Standard Randomized Clinical Trial
ISRCTN45178534
Citation: Vedder AC, Linthorst GE, Houge G, Groener JEM, Ormel EE, et al (2007) Treatment of Fabry Disease: Outcome of a Comparative Trial with
Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg. PLoS ONE 2(7): e598. doi:10.1371/journal.pone.0000598
INTRODUCTION
FabrydiseaseisanX-linkedlysosomalstoragedisordercausedbythe
deficiency of the lysosomal enzyme a-galactosidase A (aGal A,
OMIM 301500)[1,2] resulting in lysosomal accumulation of
globotriaosylceramide (GL-3) in endothelial cells and other cell
types in the body. The clinical spectrum of Fabry disease is
remarkably heterogeneous, even within affected families [3].
Complications are mostly of vascular origin and comprise of
progressive renal insufficiency, cardiac hypertrophy, arrhythmias
and cerebral infarctions [4]. During childhood the main symptoms
consist of episodes of excruciating pain in hands and feet, so-called
acroparesthesias, and absence of sweating. Recently it has become
clear that female carriers can also exhibit complications, although
the diseaseusuallyhasa moreattenuatedcourse inthese patients[5].
In 2001 the European Medical Evaluation Agency (EMEA)
approved registration of two recombinant enzyme preparations for
the treatment of Fabry disease patients in Europe. Agalsidase alfa
(Replagal
TM, Shire), produced by utilizing cultured human skin
fibroblasts, is registered for use at a dose of 0.2 mg/kg biweekly,
and agalsidase beta (Fabrazyme
TM, Genzyme), produced by
expression of the aGal A gene in Chinese hamster ovary (CHO)
cells, is registered for use at a dose of 1.0 mg/kg biweekly. The
annual costs of therapy are almost equal for both preparations at
the registered dose (around J 210.000 for a 70 kg patient), and as
such agalsidase alfa is five times more expensive per milligram
protein than agalsidase beta. Both products have shown their
effectiveness in reducing GL-3 in tissue biopsies [6,7], have
favorable effect on renal function [8,9] and reduce cardiac mass in
patients with cardiac hypertrophy [8,10]. A direct comparison of
the two products in a clinical study has so far not been performed.
Data from our laboratory, showed that both agalsidases had equal
properties with respect to amino acid composition, specific
activity, stability, and uptake by cultured fibroblasts [11]. More
recent studies confirmed these findings [12,13] except for minor
differences in glycosylation [12] and mannose-6-phosphate re-
ceptor mediated cellular uptake [13]. These results should
nevertheless be confirmed in a clinical study. All the more, since
in contrast to these laboratory data, the early clinical studies on
Fabry patients suggested that major clinical differences between
the two enzyme preparations might exist. A more prominent effect
on pain and renal function was observed using agalsidase alfa
[7],[14] as compared to agalsidase beta [6]. Later studies
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PLoS ONE | www.plosone.org 1 July 2007 | Issue 7 | e598suggested that agalsidase alfa treatment [8] gave a greater
reduction in cardiac mass than agalsidase beta treatment [10].
However, the above-mentioned studies differed in patient in-
clusion criteria, outcome parameters and infused dose [15].
Definite conclusions on differences in clinical efficacy between
the two agalsidase preparations can therefore not be drawn. The
question that we wanted to answer was whether agalsidase alfa was
clinically superior to agalsidase beta. Given the situation that the
two enzyme preparations on the one hand exhibited identical
biochemical properties, but on the other hand apparently showed
differences in clinical outcome, this question would be best
addressed by comparing the enzymes at equal dose. The choice for
comparing 0.2 mg/kg per infusion instead of 1.0 mg/kg was
a pragmatic one: the Dutch Government reimbursed the study,
including the medication, and doses higher than the registered
dose were not reimbursed. Thus, it was decided to compare the
efficacy of and tolerability towards agalsidase alfa and beta in
a prospective open label study in patients with symptomatic Fabry
disease, who were randomly assigned to receive either agalsidase
alfa or beta at an equal dose of 0.2 mg/kg biweekly. The outcome
of this investigation is here described.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and Trial
Protocols S1 and S2.
Participants
In the Netherlands, the Academic Medical Center (AMC) has
been appointed by the Dutch government as the single national
referral center for the treatment of Fabry patients, financially
supported by a governmental grant through the Dutch Health
Care Insurance Board (CVZ). The Center for Medical Genetics
and Molecular Medicine, Haukeland University Hospital (HUH),
Bergen, is a regional referral center for patients with Fabry disease
in western Norway. All patients that were referred to the centers
between May 2002 and December 2004 were asked to participate
in the study. Eligible patients had a confirmed diagnosis of Fabry
disease either by demonstration of reduction of aGal A activity in
leukocytes (males) or DNA mutation analysis (females), were at
least 18 years old and had to fulfill criteria for initiation of enzyme
replacement therapy (table 1). Patients were excluded if they were
undergoing dialysis, if they had a renal transplant, or if they were
pregnant or lactating. All patients gave written informed consent.
The study was approved by the Medical Ethical Committee
(METC) and by the Dutch Central Committee on Research
Involving Human Subjects (CCMO). This study is registered with
the Dutch Trial Register and as an International Standard
Randomised Clinical Trial, number ISRCTN45178534.
Interventions and Randomization
Patients who gave consent were randomly assigned to receive
either agalsidase alfa or agalsidase beta at a dose of 0.2 mg/kg
biweekly for a minimum of 12 months in an open label setting.
Blinding of the enzyme products was not feasible, since the quality
and storage life after rebottling could not be guaranteed. We set up
a blinded permuted block randomization with a block-size of four.
Severely affected (i.e. patients with glomerular filtration rate (GFR)
,40 ml/min, cerebrovascular accident (CVA), restrictive cardio-
myopathy and/or myocardial infarction) and less severely affected
patients were randomized separately (i.e. a different set of
randomization blocks was applied in both groups) in order to
obtain an equal distribution of disease characteristics. Each block
consisted of four envelopes that contained a paper that stated
agalsidase alfa or beta. The envelopes were numbered consecu-
tively (randomization number 1 through 4, 5 through 8, etc).
These envelopes were generated and checked by 2 persons, who
were not involved in obtaining informed consent. After informed
consent was obtained, the patient was given an (consecutive)
enrolment number (first patient was number 1 and so on). The
envelop with the corresponding randomization number was
opened by the investigator in presence of the patient. All patients
subsequently received the allocated treatment.
In case of treatment failure (see criteria below) patients were
advised to switch to agalsidase beta 1.0 mg/kg biweekly. Switching
to a higher dose of agalsidase alfa was not allowed, since the
additional costs were not covered. As part of standard clinical
practice patients with microalbuminuria or proteinuria (.30 mg/
24 h) received an angiotensin-converting enzyme inhibitor, and
acetylsalicylic acid was prescribed in case of cerebral ischemic
lesions and/or a history of transient ischemic attack (TIA).
Objectives
The objective of the current study was to compare the efficacy of
agalsidase alfa and beta at an equal dose of 0.2 mg/kg given once
every two weeks, in Fabry patients with respect to 1. decrease in
cardiac mass 2. changes in GFR, pain and GL-3 in serum and
urine 3. number of treatment failures.
Study design and sample size calculation
Prior to the start of our study, the available data from the first
clinical investigation with agalsidase alfa [7,14] suggested an
improvement in renal function following enzyme treatment. The
Table 1. Criteria for the initiation of enzyme replacement
therapy for Fabry disease in the Netherlands.
......................................................................
Major criteria 1. Severe acroparesthesias that cannot be controlled
satisfactorily with carbamazepine
2. Decreased glomerular filtration rate,80 ml/min
3. Proteinuria.300 mg/24 h
4. Documented cerebrovascular accident
5. Cardiac infarction
6. Hypertrophic nonobstructive cardiomyopathy resulting
in decreased exercise tolerance
7. Rhythm disturbances necessitating a pacemaker
8. Multiple lacunar infarctions on magnetic resonance
imaging
Minor criteria 1. Documented transient ischemic attack
2. Cardiac hypertrophy on echocardiography or magnetic
resonance imaging
3. Atrial fibrillation
4. Intraventricular conduction abnormality
5. Sensory hearing loss as shown on a hearing test
6. Severe vertigo
7. Microalbuminuria .50 mg/24 h
8. Mild to moderate acroparesthesias
9. Gastrointestinal complaints that cannot be explained by
medical conditions other than Fabry disease
Eligible patients had a confirmed diagnosis of Fabry disease either by
demonstration of reduction of aGal A activity in leukocytes (males) or DNA
mutation analysis (females), were at least 18 years old and had to fulfill at least
one major or two minor objective criteria.
doi:10.1371/journal.pone.0000598.t001
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PLoS ONE | www.plosone.org 2 July 2007 | Issue 7 | e598placebo-to-active-treatment-cross-over group showed an increase
in GFR of 9 ml/min (<10%) after 12 to 18 months of active
treatment, whereas in the first 6 months of the study (placebo
phase) these patients had shown a decline of 20 ml/min. In
contrast, no improvement in renal function was reported in the
randomized placebo controlled trial with agalsidase beta [6]. At
that time point it was therefore fair to assume that at equal doses
(0.2 mg/kg), agalsidase alfa treatment should have a better effect
on kidney function than agalsidase beta treatment. For our
analysis to have a power of 90% and an alpha-value of 5% (one-
sided), it was predicted that 42 patients (21 in each group) were
required to detect a difference in renal function improvement
between agalsidase alfa and agalsidase beta treatment. However,
during the course of the study subsequent literature reports
indicated that treatment of Fabry patients with agalsidase alfa also
stabilized rather than improved renal function (FDA briefing
document[16], FOS outcome data [8]). This became clear after
the inclusion of 29 patients. After ample considerations, we
decided to change the primary endpoint in our study from
improved renal function to reduction in left ventricular (LV) mass.
This alteration of primary endpoint was made blinded; i.e. we
were unaware of the effect of treatment on any outcome at that
time. The choice for LVmass reduction as primary endpoint was
based on literature reports indicating that agalsidase alfa treatment
might cause a greater reduction in LVmass than agalsidase beta
treatment. Using echocardiography, Beck et al. found an average
20% reduction of LVmass in Fabry patients with cardiac
hypertrophy after 12 months of treatment with agalsidase alfa
[8], while Weidemann et al. found a 10% reduction of LVmass
after 1.0 mg/kg of agalsidase beta treatment as assessed by MRI
[10]. The standard deviation in reduction in cardiac mass was
assessedat6.5%[16].Accordingly,weassumedthatatanequaldose
of 0.2 mg/kg biweekly the reduction in LVmass would be more
pronounced on agalsidase alfa than agalsidase beta treatment. Using
a powerof90% andan alpha of5%(one-sided),itwas predictedthat
at least 18 patients (9 in each group) with an increased LVmass were
required to detect a difference between the two enzyme treatments,
i.e. a 10% larger reduction in LVmass by agalsidase alfa treatment
than agalsidase beta treatment. Therefore, the inclusion was
extended to have at least 9 patients with cardiac hypertrophy and
complete echocardiography data in each group. Since in some
patients follow-up cardiac data were missing, we assumed that at
least 4 patients in each group might withdraw or had incomplete
data, we decided to include 26 patients with cardiac hypertrophy.
The additionally included patients were not selected at baseline for
cardiac hypertrophy or any other parameter other than the pre-
defined inclusion criteria.
As a separate analysis, we assessed the time to occurrence of
treatment failure in both groups. Secondary endpoints in our study
were GFR, GL-3 concentrations in urine and plasma, and pain
score (BPI-3).
Assessments of outcomes
Medical history, physical examination, routine chemical analysis
and complete blood count, plasma for biochemical assessments,
electrocardiography and 24-hour urinary samples and sediments
were collected at baseline and every 3 months during treatment.
Clinical and biochemical parameters
Left ventricular hypertrophy was assessed by ultrasound (General
Electric Vivid 7) as earlier described (LVmass .259 g in males
and .166 g in females [17]). Echocardiographic assessment of
LVmass has shown to be highly reliable with an intraclass
correlation coefficient (rho), an estimator of variability between
replicate measurements, of 0.93. In addition, reproducibility has
shown to be very high with a variation in mean LVmass of 0–
2.6%, with some effect of regression to the mean in patients with
severe cardiac hypertrophy [18]. Glomerular filtration rate (GFR)
was measured at baseline and after 12 and 24 months of treatment
by iothalamate/hippuran infusions [19](at the AMC) or iohexol
infusions [20](at the HUH). Both tests have shown to be very
accurate with an intratest coefficient of variation of 1.93% and
5.59%, respectively. In a few instances cardiac ultrasound and
GFR measurements were not performed within the required
timeframe (62 months of planned assessment) for logistical
reasons. This happened in 5 cases for both measurements at
baseline, and 9 and 5 cases at 12 months for cardiac ultrasound
and GFR, respectively. Pain was assessed through the Brief Pain
Inventory (BPI) as earlier described [7] at baseline and after 12
and 24 months and was only obtained from the AMC patients.
Brain MRI was assessed at baseline and at 12 and 24 months for
the absence or presence of lacunar infarctions (score 0 or 1
respectively), where a score of 2 represents a new (lacunar) infarction
(see table 2). Specialists who evaluated all ECGs, echocardigrams,
GFR measurements and MRIs, were blinded for the assignment of
patients to treatment groups and were not informed of previous
results at the time of testing. Overall severity of disease was assessed
using the Mainz Severity Score Index (MSSI) [21]
Concentrations of GL-3 in urine was measured as described
before [22,23]. Levels of GL-3 in plasma were measured by high
pressure liquid chromatography (HPLC) (Groener et.al., sub-
mitted manuscript). Lipids were extracted from 50 ml plasma
according to Folch [24]. Glycosphingolipids were deacylated by
a modification of the microwave-assisted hydrolysis, as described
by Taketomi et al. [25]. The produced lysoglycosphingolipids were
derivatized with O-phtaladelhyde, separated on a reverse phase
HPLC column and measured with a fluorescence detector. GL-3
levels were measured at baseline and every 3 months during
treatment. Plasma samples were also evaluated for the presence of
antibodies towards the enzyme products by ELISA, as previously
described [23]. A dilution of 1:8 was determined as the lower
detection limit, which is applicable to both agalsidase alfa as well
as beta. Lipid and antibody data were only collected for the Dutch
cohort (29/34 patients).
Definition of treatment failure
Treatment failure was defined as progression of renal disease (33%
increase in serum creatinine, need for dialysis or transplantation),
progression of cardiac disease (new infarction, need for cardiover-
sion, or anti-arrythmic drugs, heart-failure necessitating hospital-
ization), or occurrence of a new CVA as diagnosed by a neurologist
or new lacunar infarctions on magnetic resonance imaging (MRI)
as assessed by an experienced neuroradiologist.
Statistical methods
Efficacy of treatment was analyzed as a change in parameters
between baseline and 12 and 24 months of treatment for every
parameter studied. Results are expressed as median and range.
Differences between the different treatment groups were calculat-
ed using the Mann Whitney U-test or chi-squared test. Differences
between baseline and 12 months and baseline and 24 months of
treatment were calculated by the Wilcoxon signed rank test.
Correlations between variables are described by assessment of
Spearman rank correlation coefficients. The percent of patients
experiencing no treatment failure was studied by Kaplan-Meier
analysis. The logrank test was used to compare time to treatment
Treatment of Fabry Disease
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significant.
RESULTS
Baseline characteristics
Forty-five patients were assessed for eligibility (figure 1). One male
patient did not meet the inclusion criteria due to a renal
transplant. Eight patients chose to be treated with agalsidase beta
at 1.0 mg/kg, either because family members already received this
treatment (3 cases), or for other unrelated reasons. These patients
did not differ with respect to disease severity from the patients
participating in the study. Thirty-six patients, 18 males and 18
females, were included in the study. Two mildly affected female
patients withdrew at their own request after 6 months of agalsidase
alfa therapy. Neither of these women had suffered from treatment
failure during the 6 months study period. The thirty-four patients
remaining had at least 12 months of follow up. A sub-group of
patients (25/34) was followed for more than 24 months of
treatment. The baseline characteristics were similar for both
treatment groups (table 2).
Concomitant drug therapy at baseline included angiotensin-
converting enzyme inhibitors or angiotensin-I blockers (8 patients
in the agalsidase alfa and 4 in the agalsidase beta group), beta
blockers (4 in the agalsidase alfa and 3 in the agalsidase beta
group), diuretics (1 in the agalsidase alfa 3 in the agalsidase beta
group ), calcium channel blockers (3 in the agalsidase beta group)
and acetylsalicylic acid (11 in the agalsidase alfa and 11 in the
agalsidase beta group). All co-medications were continued
throughout the study. Changes in co-medication during the trial
Figure 1. Study flow chart. D clinical endpoint: change of primary endpoint from improvement of renal function to reduction in left ventricular mass.
doi:10.1371/journal.pone.0000598.g001
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in the agalsidase beta group) a dose change of angiotensin-
converting enzyme inhibitor or angiotensin-I blocker was made,
and in one patient (agalsidase alfa) an angiotensin-converting
enzyme inhibitor was started during the course of the study. Four
patients (3 in the agalsidase alfa and 1 in the agalsidase beta group)
were treated for hypertension (untreated blood pressure .140/
90 mmHg). All were well controlled.
Effects of agalsidase alfa and beta therapies on
clinical parameters
Primary endpoint: cardiac hypertrophy Echocardiographic
measurements were performed in 29 patients at baseline (14 in the
agalsidase alfa and 15 in the agalsidase beta group). Twenty-six of
these patients had an increased LVmass at baseline (13 in the
agalsidasealfa and 13 inthe agalsidase beta group). Of these patients
follow up data were available from 20 patients at 12 months (10 in
both treatment groups) and 17 patients at 24 months (7 agalsidase
alfa, 10 agalsidase beta). There was no difference in median cardiac
mass between the two groups at baseline (agalsidase alfa: 288 g,
range177to 479,agalsidasebeta:316 g, range 213 to517,p=0.48).
At 12 months, no significant reduction in cardiac mass was seen in
both groups. Median change was 211% (223 g, range 2167 to
136 g, p=0.51) following agalsidase alfa treatment and 215%
(246 g,range2226to131 g,p=0.17)after12monthsofagalsidase
beta treatment. These results were not different between the
treatment groups (p=0.3). The median change in the combined
groupsafter12monthsoftreatmentwas211%(235 g,range2226
to 136 g; p=0.10), and this was also non-significant. Data available
of patients who reached 24 months follow up gave a consistent
pattern. Sub-analysis of the data showed that all patients with poor
renal function (GFR,60 ml/min, n=4, including patient 27 who
had a baseline creatinine clearance (calculated from 24 h urine
collection) of 41 ml/min) had an increase of LVmass during
treatment. Without these patients a significant reduction in
LVmass (14%, p=0.03) after 12 months of treatment was
observed for the combined groups, which did not reach
significance for the two treatment groups separately (p=0.09 and
0.17 for agalsidase alfa and beta, respectively).
Secondary endpoint: Glomerular filtration rate (GFR)
and proteinuria Median GFR was not different between the
two treatment groups at baseline (agalsidase alfa: 99 ml/min,
range 22 to 136, agalsidase beta: 108, range 53 to 154, p=0.50).
Following 12 months of treatment no significant change could be
observed. A slight increase of 5 ml/min in both groups was noted
(ranges: agalsidase alfa 228 to 35 p=0.37, and agalsidase beta
215 to 25, p=0.23). Two patients (patient 25 and 31, table 2),
both presenting a low GFR at start of treatment, showed
progression of renal disease during therapy as reflected by
a .33% increased serum creatinine. In patients evaluated after
24 months of treatment (n=21), no additional changes in renal
function were observed. Exclusion of the patients with a baseline
GFR ,60 ml/min did not change the results.
Urinary protein data were available for the Dutch patients.
There was no difference in baseline levels between the two
treatment groups: agalsidase alfa: 0.25 g/24 h (range 0.06 to 2.65),
agalsidase beta: 0.24 g/24 h (range 0.10 to 0.68), p=0.59. The
values did not change following 12 and 24 months of treatment
(agalsidase alfa at 12 months: 0.30 g/24 h (range 0.08 to 2.83,
p=0.35) and at 24 months: 0.27 g/24 h (range 0.10 to 1.65,
p=0.70), agalsidase beta at 12 months: 0.20 g/24 h (range 0.08 to
0.50, p=0.33) and at 24 months: 0.15 g/24 h (range 0.06 to 0.57,
p=0.28)). These changes in proteinuria were not different
between the two treatment groups (p=0.16 and p=0.33, for 12
and 24 months respectively). A change in dose of angiotensin-
converting enzyme inhibitors or angiotensin-I blockers did not
influence the results.
Secondary endpoint: Pain Score Data on pain score were
available for 15 patients in the agalsidase alfa group and for 13
patients in the agalsidase beta group. No pain scores were
available from the patients included at the HUH and one patient
from the AMC. Since the Norwegian patients were not different
with respect to disease severity and gender (three females and two
males), we expected no difference in outcome. At baseline, pain
scores were not different (agalsidase alfa: median 4, range 0 to 8,
agalsidase beta: median 4, range 0 -7).
No significant reduction of pain score (BPI-3) after 12 months of
treatment was noted in any of the groups: alfa 0 (range 25 to 1),
beta 21.5 (range 24 to 3). Evaluation after 24 months of
treatment (n=20) did not change this result.
Secondary endpoint: Antibodies and biochemical
parameters (GL-3 in urine and plasma) Anti-agalsidase
antibodies and GL-3 levels in urine and plasma were only
analyzed in the Dutch Fabry patients. Antibodies were found in
10/16 males (4/8 agalsidase alfa, 6/8 agalsidase beta, x
2=1.07,
p=0.3); no female patient developed antibodies. At 6 months, titer
levels ranged from 1/64 to 1/32768 in agalsidase alfa treated
males and from 1/256 to 1/16384 in agalsidase beta treated
males. After 12 months of treatment only two males (agalsidase
beta) had a decline of antibody titer. Infusion related side effects
were seen in 3/10 antibody positive male patients, 1/4 treated
with agalsidase alfa and 2/6 treated with agalsidase beta. These
side effects were chills and fever, followed by acroparesthesias.
All but two females in the agalsidase beta group had elevated
urinary GL-3 levels (.400 nmol/24 h) at baseline. In the patients
with elevated baseline levels a median decrease of 284 nmol/24 h
(range 24939 to 1350, p=0.04) in the agalsidase alfa group and
265 nmol/24 hr (range 21216 to 1450, p=0.66) in the agalsidase
beta group was found after 12 months of treatment. This reduction
in GL-3 was not significantly different between the two groups
(p=0.65). As antibodies may interfere with GL-3 clearance we
performed an exploratory subgroup analysis. This revealed a major
difference in urinary GL-3 reduction upon therapy between male
patients with and without antibodies. In all antibody positive
males, urinary GL-3 levels failed to decline after 12 months of
treatment (126 nmol/24 h, range 21140 to 1450, p=0.31
(n=10)) whereas a reduction could be detected in males without
antibodies (2989 nmol/24 h, range 24939 to 216, p=0.04
(n=6)). This difference in urinary GL-3 reduction between males
with and without antibodies was statistically significant (p=0.02),
and a similar trend was also observed in male patients (n=12)
analyzed after 24 months of treatment.
Plasma GL-3 was elevated at baseline (.3.18 umol/l) in 10/16
agalsidase alfa (2 females) and 8/13 agalsidase beta (1 female)
treated patients. In those patients who showed elevated GL-3
levels at baseline, a decrease of 2.56 (range 25.81 to 0.32,
p=0.009) after 12 months of agalsidase alfa treatment was seen.
Similar results were seen in the agalsidase beta treated patients
with a reduction of 1.84 (range 25.17 to 20.23, p=0.012). This
reduction of GL-3 was not different between the two treatment
groups (p=0.46). Twenty-four months follow up data (n=15)
showed a similar pattern. Antibodies resulted in a less robust
decrease of plasma GL-3 levels in male patients after 12 months of
treatment (ab+ 22.44 umol/l, range 25.17 to 20.23, p=0.005
(n=10); ab- 23.5 umol/l, range 25.81 to 21.42, p=0.04 (n=6)).
Again a similar trend was noted in the male patients (n=13)
analyzed after 24 months of treatment.
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Treatment failure within 24 months of treatment was seen in 6
male patients (3 in each treatment group) and 2 female patients
(both agalsidase alfa). The time to the occurrence of treatment
failure did not differ between the two treatment groups; x
2=0.38
p=0.54 (figure 2A). Additional analysis including the two female
patients that withdrew volunatrily, assuming they had been ‘event-
free’ for 24 months, does not result in a different conclusion
(x
2=0.18, p=0.66). The three male patients (patients 9,10 and 11,
table 2) with treatment failure on agalsidase beta showed
progression of MRI abnormalities. This was also observed in
one male (patient 33) and one female patient (patient 21) in the
agalsidase alfa group. Renal insufficiency (increase of serum
creatinine .33%) progressed in one male (patient 31) and one
female patient (patient 25) treated with agalsidase alfa, with
baseline GFR of 22 and 30 ml/min, respectively. The increase in
serum creatinine corresponded with a decrease in GFR of 27.2%
and 26.8%, respectively (see table 2). One male patient (patient 27)
died of multiple cerebral infarctions after 20 months of agalsidase
alfa treatment. Data analysis of patients receiving ERT for more
than 24 months showed treatment failure in four additional
patients (2 in each treatment group). One male patient (patient 12)
and one female patient (patient 1) suffered from atrial fibrillation
after 42 and 36 months of agalsidase beta treatment, respectively.
Atrial fibrillation also occurred in a male patient (patient 32)
treated with agalsidase alfa for 30 months. Progression of renal
insufficiency was seen in a female patient (patient 22) following 30
months of agalsidase alfa treatment. All patients showing
treatment failure were switched to infusion with agalsidase beta
at standard dose (1.0 mg/kg biweekly). Even after this switch,
further progression of disease was seen in 5 patients (2 initially on
agalsidase alfa and 3 initially on agalsidase beta, all progression of
MRI abnormalities). Pre-treatment disease severity as assessed by
the MSSI score was associated with the occurrence of treatment
failure in males (figure 2B): average MSSI was 44 (range 17–59) in
male patients with treatment failure and 21 (range 12–37) in those
without treatment failure (p=0.02). Age was also associated with
treatment failure; all patients with progression were significantly
older than the patients without treatment failure (p=0.02), all
being above 40 years of age (figure 2C, median all patients 50 (42–
61), females 51 (47–58), males 49 (42–61)).
The induction of antibodies did not correlate with the
occurrence of treatment failure: 6/10 male patients with
antibodies and 2/6 without antibodies developed treatment
failure. Further exploratory analysis was performed on the relation
between GL-3 levels and treatment failure. When urinary GL-3
levels of patients who suffered from treatment failure were
compared with those who did not, no differences in baseline
levels and extent of decrease were shown. However, a trend
towards higher baseline urinary GL-3 levels was seen in patients
with treatment failure (2083 nmol/24 h, range 520 to 5681
(n=10), as compared to 802 nmol/24 h, range 246 to 2233
(n=17), p=0.06). Reduction in urinary GL-3 was 19% and 22%
after 12 and 24 months in patients with, and 28% and 42% in
patients without treatment failure (p=0.60 and p=0.39, re-
spectively). Plasma GL-3 levels of patients who suffered from
treatment failure were not different from the levels found in
patients who did not: average baseline levels of plasma GL-3 in
Figure 2. A: Kaplan Meier survival analysis of percent patients with no treatment failure in both treatment groups. B: Number of patients with
treatment failure displayed per 10 MSSI points. C: Number of patients with treatment failure displayed per age decade.
doi:10.1371/journal.pone.0000598.g002
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and non-treatment failures 3.31 umol/l (range 0.77 to 7.46
(n=17)) (p=0.28). Reductions in GL-3 were 30% and 22% in
treatment failures versus 15% and 39% in non-treatment failures,
respectively, at 12 (p=0.25) and 24 months (p=0.61).
Adverse events
Serious adverse events, which did not fulfill the criteria for treatment
failure, resulting in hospitalization or initiation of medication were
seen in one agalsidase alfa and three agalsidase beta treated patients.
One male patient (patient 32) treated with agalsidase alfa presented
with intermittent claudication of the right leg due to vascular stenosis
after 15 months of therapy, which was treated with lifestyle advice.
During agalsidase beta treatment one female patient (patient 1)
reported acute hearing loss after 18 months, one male (patient 9)
presented with severe vertigo after 12 months and one male (patient
11)showedprogressivesensomotorpolyneuropathyandoesophagitis
after 12 months of treatment. These last two events were considered
not to be related to Fabry disease. As reported above, only three
antibody positive male patients experienced infusion related chills
and fever, 1 treated with agalsidase alfa and 2 treated with agalsidase
beta. The incidence of mild to moderate adverse events (grade 1 or 2
nausea, dizziness, headache and diarrhea) was low and not different
between the two treatment groups.
DISCUSSION
Since ERT became available for Fabry disease, it has been
extensively debated which of the two available enzyme prepara-
tions is most potent. The only direct comparative studies that have
been performed are either in vitro studies or studies in mice,
showing no important differences. [12,13,15,26–29]. Studies in
Fabry patients have so far focused on the clinical and biochemical
effects of both products separately. All studies with agalsidase alfa
were performed with a dose of 0.2 mg/kg every two weeks. The
first placebo-controlled clinical trial with agalsidase alfa has shown
a beneficial effect on pain. In that study, and the EMEA report,
stable renal function in the agalsidase group and improvement in
creatinine clearance after cross over from placebo to active
treatment was reported, as well as improved renal histology and
decline a in GL-3 levels in the urine [7,14]. Subsequently, in an
open study, improvement of sweat function and warm or cold
sensation in feet was reported [30]. More recently, renal outcome
was described following 4–4.5 years of agalsidase alfa therapy,
showing stabilization in patients with preserved renal function, but
gradual deterioration in advanced kidney disease [31]. The Fabry
Outcome Survey, a large database including mainly data on
treated patients, created for post-marketing surveillance, reported
stabilisation of renal function as well as decreases in cardiac mass,
improvement of pain and quality of life following 12 to 24 months
of agalsidase alfa treatment [8,32,33]. All clinical studies involving
agalsidase beta were performed at 1.0 mg/kg every two weeks.
The first placebo controlled trial with agalsidase beta focused
mainly on surrogate endpoints, including clearance of GL-3 from
renal endothelium as well as a reduction in GL-3 accumulation in
the heart, skin and plasma [6]. After 30 to 36 months of open label
treatment, renal function had stabilized in most, but not all,
patients and a persistent decrease in plasma GL-3 and a further
clearance of accumulation from the skin was reported [9]. Two
open label studies reported decrease of LVmass and an
improvement in myocardial function following 12 months of
treatment [10] [34]. Recently Breunig et al. [35] recorded in an
open label study in 26 patients that clinical endpoints such as
death, cardiac and cerebrovascular events and renal failure
occurred 12 times in 9 patients, all with advanced renal
insufficiency. The very recently reported results of a phase IV
placebo-controlled study, in which the time to similar clinical
events was analyzed in 82 patients with mild to moderate kidney
disease, revealed that treatment resulted in less complications, but
also that this beneficial effect was preferentially seen in patients
with less severe kidney disease [36]. In summary, the early studies
reported mainly a beneficial effect on clinical outcome (pain, renal
function) with agalsidase alfa, and reductions in stored GL-3 in the
agalsidase beta studies. The following studies showed less effect on
renal function, but consistent reductions in cardiac mass, with
especially promising improvements using agalsidase alfa. In the
most recent studies, however, there is growing evidence that
advanced disease, especially kidney disease, negatively influences
the outcome. Although agalsidase alfa was believed to exhibit the
most positive effects on clinical endpoints, a head-to-head
comparative study was needed to address whether indeed there
was superiority of agalsidase alfa. Therefore, we have studied the
effectiveness of treatment with agalsidase alfa and agalsidase beta
at equal doses (0.2 mg/kg biweekly) in Fabry disease patients in
a randomized open label study. Our primary endpoint was based
upon previous reports showing a reduction in LVmass upon
treatment [8,10]. The response on cardiac hypertrophy was less
than expected from these studies with patients showing an increase
as well as a decrease in LVmass, resulting in an overall reduction
that was not statistically significant. The changes in LVmass did
not differ between the two treatment groups, neither after
analyzing treatment effects in male and female patients separately.
A closer look at the effects of ERT on LVmass suggested that the
trend towards a decrease was slightly more prominent in the
agalsidase beta group than in the agalsidase alfa group (15% vs.
11% after 12 months and 11% vs. 5% after 24 months), but this
difference was not statistically significant. The question remains
whether this variable effect can also be attributed to pretreatment
severity of disease and age as compared to the reports in the
literature. In the study by Weidemann et al.[10], a 10% decrease
in LVmass as measured by MRI and following 12 months of
treatment with a standard dose of agalsidase beta (1.0 mg/kg
biweekly) was observed. When comparing the age of this group
with our cohort, our cohort appears to be slightly older (47 years
vs. 42 years), which may negatively influence therapeutic effects.
In addition, mean left ventricular mass at baseline was lower
(201 g) than in our group (316 g). However, MRI may give
different LVmass measurements than echocardiography, and it is
therefore difficult to compare the baseline degree of hypertrophy
in both cohorts. It is also possible that a five times higher dose used
in the Weidemann et al. study resulted in a more consistent
beneficial response in this group. As mentioned above, the same
group described that in patients with severe renal impairment,
cardiac hypertrophy was more extensively present and even
progressed upon therapy [35]. Similarly, in our cohort the patients
with a GFR ,60 ml/min were the ones that had a further
increase in cardiac mass despite ERT. Re-analysis of the cardiac
data, without these patients and after combining both treatment
groups, indeed revealed a significant reduction of LVmass of 14%
after 12 months of treatment. This underscores that severe renal
impairment in Fabry disease is associated with irreversible cardiac
hypertrophy [35]. Beck et al.[8] reported a 20% reduction in
LVmass following 12 months of standard dose agalsidase alfa
treatment (0.2 mg/kg biweekly). This is more prominent than the
response observed in our agalsidase alfa group. Mean LVmass at
baseline was higher than in our agalsidase alfa treatment cohort
(70 g/m
2.7=300 g for a 1.70 m individual, versus 221 g in our
agalsidase alfa group), which may indicate more advanced disease.
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cardiac evaluation is performed in the Beck et al study, the
baseline GFR and age as presented in this paper was not different
from our group.
In line with the similarity in clinical responses to agalsidase alfa
and beta treatments at 0.2 mg/kg biweekly, the reductions in
plasma and urinary GL-3 in both treatment groups were not
significantly different. We noted that reduction of urinary GL-3
tended to be better in male Fabry patients treated with agalsidase
alfa than agalsidase beta. The higher number of male patients
developing antibodies towards agalsidase beta (6/8) as compared
to agalsidase alfa therapy (4/8) may explain this. We and others
have reported earlier that antibody formation interferes with GL-3
clearance [23,37]. Also in the current study, an association
between the emergence of antibodies and absence of decline in
urinary GL-3 was established. Notably, although the occurrence of
antibodies correlated with less reduction of GL-3 levels in Fabry
patients, this was not associated with significantly poorer responses
in key clinical endpoints such as cardiac hypertrophy, renal
function and brain complications. Previous studies by Eng et al.[6]
and Schiffmann et al.[38] reported emergence of antibodies in
88% (51/58) agalsidase beta 1.0 mg/kg treated and 56% (14/25)
agalsidase alfa 0.2 mg/kg treated male patients. These results are
difficult to compare since different enzyme dosages and different
methods for antibody detection were employed in the studies. The
antibody results from our study need to be interpreted with great
caution as we only performed analysis in a small group of patients.
It is, however, possible that agalsidase alfa is intrinsically less
antigenic than agalsidase beta in male Fabry patients.
One of our most important observations is that the efficacy of
ERT, whether using agalsidase alfa or beta, in general is
disappointing. Both groups had a high rate of treatment failure,
approaching 25% of patients within the 24 months study period,
and increasing to about a third of the patients when patients who
received treatment for more than 24 months were also included
(12/34 patients). The incidence of treatment failure was not
different between the agalsidase alfa and beta treatment groups (7/
18 patients on agalsidase alfa and 5/16 patients on agalsidase
beta). Increase in cardiac mass was unexpected to occur, and as
such was not included in the treatment failure criteria. In
retrospect, 7 patients experienced an increment in LVmass, 4 in
the agalsidase alfa and 3 in the agalsidase beta group at 12 months.
A further analysis of the patients with disease progression on ERT
clearly showed that treatment failure occurred predominantly in
patients with more extensive pre-treatment manifestations, as
evidenced by a higher MSSI score. Consistent with this, the
patients with treatment failures were generally older. Before the
age of 40 and with an MSSI score ,17, no failures occurred. In
addition, all patients with a GFR ,60 ml/min had progression of
disease, including two patients who had a further decline in renal
function. This is in line with the previously discussed more recently
published studies on long term treatment in patients with
advanced kidney disease, in whom further deterioration of renal
insufficiency during ERT was observed [9,31,35].
Since the overall treatment effects were less prominent than
anticipated, the comparison of the efficacy of agalsidase alfa versus
agalsidase beta at equal dose has become difficult. When
considering the observed reductions in cardiac mass, including
the larger variability in these reductions than expected, it becomes
apparent that the number of patients in our study has been too
small to provide a definite answer to the question whether these
products have different effects at the same dose. Despite this
limitation, it remains clear that in both groups, with comparable
baseline disease parameters, the number of failures to treatment was
not different. It is uncertain whether a higher dose of agalsidase alfa
or beta would have resulted in better responses (less treatment
failures)sincethedamageinthisseverelyaffectedolderpatientgroup
will probably not respond to any therapy. This is supported by the
observation that further disease progression is seen in a considerable
subset of these patients after switching to 1.0 mg/kg of agalsidase
beta. In this group with advanced disease, enzyme therapy may still
have some effect as it has been suggested that the slope of decline in
renal function may be decreased [35,38].
When we compare the outcome in the non-treatment failures,
no difference in response with respect to cardiac mass and GFR
was found. It is possible that a minor difference in effect between
the two enzymes will be detected if a much larger group of patients
would be studied. However, it is very unlikely that these trials will
be performed given the rarity of the disorder as well as the fact that
it will be almost impossible to prospectively collect large numbers
of unbiased data in a post-marketing setting.
As has also been suggested by others, early treatment may be
the best option for Fabry disease patients to profit from ERT
[8,9,35,39]. Since treatment is very expensive, not without side
effects, and only possible through frequent intravenous infusions
that can carry a high burden on (young) patients, it is now
a challenge to find the threshold where therapy is still capable of
preventing or reversing organ damage caused by the disease. A
long-term study in young, pre-symptomatic males who are
randomized to either immediate therapy or later institution of
ERT could eventually resolve this issue. International guidelines
for these costly therapies should derive from such studies.
In conclusion, our study has revealed similar effects on clinical
parameters (cardiac hypertrophy, glomerular filtration rate) and on
plasma and urinary GL-3 reduction after 12 and 24 months of
treatment with either agalsidase alfa or beta at a dose of 0.2 mg/kg
biweekly. Although the number of patients in this study is small, it is
unlikely that large differences in clinical potency exist between the
two enzymes at equal dose. Treatment failure occurred relatively
often in both groups, and further progression of disease could not be
prevented after a switch to 1.0 mg/kg agalsidase beta. Treatment
failure seems related to age and severe pre-treatment disease,
supporting the hypothesis that early initiation of ERT in the disease
course may be the only way to prevent long term complications.
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